Vistagen Therapeutics, Inc. - SIC # 2830 -

Ticker Exchange SIC # Website Latest Ticker
VTGN Nasdaq 2830 www.vistagen.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Vistagen Therapeutics, Inc.

Vistagen Reports Fiscal Year 2027 First Quarter Financial Results and Corporate Update - Aug 14th, 2026 6:32 am
Vistagen Announces Topline Results for Repeat Dose Study of Fasedienol for Acute Treatment of Social Anxiety Disorder - Aug 6th, 2026 6:30 am
SRX Global Acquires Stake in Vistagen Therapeutics - Aug 4th, 2026 9:35 am
SRX Global Acquires Stake in Vistagen Therapeutics (NASDAQ: VTGN) - Aug 4th, 2026 3:00 am
Vistagen Appoints Douglas J. Williamson to its Board of Directors - Jul 31st, 2026 6:30 am
Is Vistagen Therapeutics, Inc. (VTGN) Stock Facing New Challenges After PALISADE-4 Clinical Trial Results? - Jul 15th, 2026 3:22 am
Vistagen Announces Topline and Post-Hoc Data from PALISADE-4 Phase 3 Public Speaking Challenge Trial of Fasedienol for the Acute Treatment of Social Anxiety Disorder - Jun 30th, 2026 6:00 am
Vistagen Reports Fiscal Year 2026 Financial Results and Provides Corporate Update - Jun 15th, 2026 2:30 pm
Vistagen Achieves Minimum ICH Safety Exposure Recommendations Across Clinical Program for Fasedienol for the Acute Treatment of Social Anxiety Disorder - Jun 9th, 2026 6:30 am
Is Vistagen Therapeutics, Inc. (VTGN) a Breakout Anxiety Drug Stock After New Phase 3 Extension Results? - May 19th, 2026 5:08 am
VistaGen Therapeutics, Inc. Q3 2026 Earnings Call Summary - Feb 13th, 2026 6:30 am
Vistagen Therapeutics Inc (VTGN) Q3 2026 Earnings Call Highlights: Progress in Clinical Trials ... - Feb 12th, 2026 10:02 pm